You are viewing the site in preview mode
Skip to main content
| |
All
|
(n = 86)
|
UFT
|
(n = 37)
|
S-1
|
(n = 49)
|
p value
|
|---|
|
Sex (male)
|
56
|
(65.1)
|
25
|
(67.6)
|
31
|
(63.3)
|
0.85
|
|
Age (years old)
|
57.5
|
± 12.2
|
59.1
|
± 13.9
|
56.3
|
± 10.7
|
0.31
|
|
Operative method
| | | | | | |
0.10
|
|
Distal gastrectomy
|
65
|
(75.6)
|
26
|
(70.3)
|
39
|
(79.6)
| |
|
Total gastrectomy
|
18
|
(20.9)
|
11
|
(29.7)
|
7
|
(14.3)
| |
|
Proximal gastrectomy
|
3
|
(3.5)
|
0
|
(0)
|
3
|
(6.1)
| |
|
Site
| | | | | | |
0.33
|
|
Antrum and low body
|
61
|
(70.9)
|
26
|
(70.3)
|
35
|
(71.4)
| |
|
Middle and high body
|
18
|
(20.9)
|
9
|
(24.3)
|
9
|
(18.4)
| |
|
Whole stomach
|
1
|
(1.2)
|
1
|
(2.7)
|
0
|
(0)
| |
|
Remnant
|
6
|
(7.0)
|
1
|
(2.7)
|
5
|
(10.2)
| |
|
Size (cm)
|
4.4
|
± 2.0
|
4.3
|
± 2.0
|
4.6
|
± 2.1
|
0.49
|
|
Bormann type
| | | | | | |
0.047*
|
|
I or II
|
21
|
(24.4)
|
5
|
(13.5)
|
16
|
(32.7)
| |
|
III or IV
|
65
|
(75.6)
|
32
|
(86.5)
|
33
|
(67.3)
| |
|
Lauren classification
| | | | | | |
0.49
|
|
Intestinal type
|
31
|
(36.0)
|
13
|
(35.1)
|
18
|
(36.7)
| |
|
Diffuse type
|
39
|
(45.3)
|
19
|
(51.4)
|
20
|
(40.8)
| |
|
Mixed type
|
16
|
(18.6)
|
5
|
(13.5)
|
11
|
(22.4)
| |
|
Cell differentiation
| | | | | | |
0.54
|
|
Well-differentiated
|
7
|
(8.2)
|
4
|
(11.1)
|
3
|
(6.1)
| |
|
Moderately differentiated
|
23
|
(27.1)
|
11
|
(30.6)
|
12
|
(24.5)
| |
|
Poorly- or un-differentiated
|
55
|
(64.7)
|
21
|
(58.3)
|
34
|
(69.4)
| |
|
LN metastasis (number)
|
4.5
|
± 5.7
|
5.2
|
± 7.8
|
3.9
|
± 3.3
|
0.35
|
|
LN harvested (number)
|
34.9
|
± 18.6
|
33.9
|
± 19.3
|
35.6
|
± 18.2
|
0.67
|
|
Lymphovascular invasion
|
56
|
(65.1)
|
25
|
(67.6)
|
31
|
(63.3)
|
0.85
|
|
Perineural invasion
|
57
|
(66.3)
|
25
|
(67.6)
|
32
|
(65.3)
|
0.99
|
|
T stage (AJCC 8th)
| | | | | | |
<0.001*
|
|
1
|
0
|
(0)
|
0
|
(0)
|
0
|
(0)
| |
|
2
|
19
|
(21.8)
|
8
|
(21.6)
|
11
|
(22.4)
| |
|
3
|
42
|
(48.3)
|
8
|
(21.6)
|
33
|
(67.3)
| |
|
4
|
26
|
(29.9)
|
21
|
(56.8)
|
5
|
(10.2)
| |
|
N stage (AJCC 8th)
| | | | | | |
0.48
|
|
0
|
2
|
(2.3)
|
0
|
(0)
|
2
|
(4.1)
| |
|
1
|
33
|
(38.4)
|
15
|
(40.5)
|
18
|
(36.7)
| |
|
2
|
36
|
(41.9)
|
14
|
(37.8)
|
22
|
(44.9)
| |
|
3
|
15
|
(17.4)
|
8
|
(21.6)
|
7
|
(14.3)
| |
|
Pathological stage (AJCC 8th)
| | | | | | |
0.23
|
|
II
|
33
|
(38.4)
|
11
|
(29.7)
|
22
|
(44.9)
| |
|
III
|
53
|
(61.6)
|
26
|
(70.3)
|
27
|
(55.1)
| |
|
Follow-up (months)
|
52.6
|
± 31.2
|
65.9
|
± 36.9
|
43.3
|
± 22.6
|
0.003*
|
- Data are mean ± SD or n (%)
- UFT tegafur-uracil, S-1 tegafur-gimeracil-oteracil, LN lymph node, AJCC American Joint Cancer Committee
- *p value < 0.05 after comparing between the UFT and S-1 groups
